Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents
Identifieur interne : 000968 ( Istex/Corpus ); précédent : 000967; suivant : 000969Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents
Auteurs : Larisa G. Rudenko ; Nancy H. Arden ; Elena Grigorieva ; Anatoli Naychin ; Andrei Rekstin ; Alexander I. Klimov ; Svetlana Donina ; Julia Desheva ; Robert C. Holman ; Angel Deguzman ; Nancy J. Cox ; Jacqueline M. KatzSource :
- Vaccine [ 0264-410X ] ; 2001.
English descriptors
- Teeft :
- Antibody response, Antibody responses, Antibody titers, Attenuated, Attenuated vaccine, Chronic diseases, Clin microbiol, Combination vaccine groups, Combination vaccine strategies, Disease control, Dos, Elderly people, Elderly persons, Gmt, Immunogenicity, Intranasal, Nasal, Nursing home, Nursing home residents, Nursing homes, Other vaccine groups, Placebo, Placebo group, Post rise, Posta riseb, Postvaccination, Postvaccination gmts, Postvaccination serum, Postvaccination titers, Prevaccination, Prevaccination titers, Reassortant, Responder, Rudenko, Serum antibody response, Study participants, Titer, Treatment groups, Trivalent, Trivalent vaccine, Trivalent vaccines, Vaccination, Vaccine, Vaccine antigens, Vaccine group, Vaccine groups, Vaccine immunogenicity, Virus vaccine, Virus vaccines.
Abstract
Abstract: The immunogenicity and efficacy of Russian live attenuated and US inactivated trivalent influenza vaccines administered alone or in three different combinations were evaluated in a randomized, placebo-controlled, double-blinded study of 614 elderly or chronically ill nursing home residents in St. Petersburg, Russia during the 1996–97 influenza season. Postvaccination serum antibody responses were more frequent among individuals administered the combination vaccines than among those vaccinated with live or inactivated vaccine alone. Only individuals who received live vaccine, alone or in combination with inactivated vaccine, achieved significant postvaccination increases in virus-specific nasal IgA. Efficacy in preventing laboratory-confirmed influenza in vaccinated versus nonvaccinated individuals was 67% (95%CI, 36–81%) for recipients of a combination of the vaccines compared with 51% (95%CI, −17–79%) for recipients of live vaccine alone and 50% (95%CI, −26–80%) for recipients of inactivated vaccine alone. These results suggest that administration of a combination of influenza vaccines may provide a strategy for improved influenza vaccination of elderly people.
Url:
DOI: 10.1016/S0264-410X(00)00153-5
Links to Exploration step
ISTEX:06F7B956F585967015B4D7427F7977B97918802DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents</title><author><name sortKey="Rudenko, Larisa G" sort="Rudenko, Larisa G" uniqKey="Rudenko L" first="Larisa G" last="Rudenko">Larisa G. Rudenko</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Arden, Nancy H" sort="Arden, Nancy H" uniqKey="Arden N" first="Nancy H" last="Arden">Nancy H. Arden</name><affiliation><mods:affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</mods:affiliation></affiliation></author><author><name sortKey="Grigorieva, Elena" sort="Grigorieva, Elena" uniqKey="Grigorieva E" first="Elena" last="Grigorieva">Elena Grigorieva</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Naychin, Anatoli" sort="Naychin, Anatoli" uniqKey="Naychin A" first="Anatoli" last="Naychin">Anatoli Naychin</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Rekstin, Andrei" sort="Rekstin, Andrei" uniqKey="Rekstin A" first="Andrei" last="Rekstin">Andrei Rekstin</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Klimov, Alexander I" sort="Klimov, Alexander I" uniqKey="Klimov A" first="Alexander I" last="Klimov">Alexander I. Klimov</name><affiliation><mods:affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</mods:affiliation></affiliation></author><author><name sortKey="Donina, Svetlana" sort="Donina, Svetlana" uniqKey="Donina S" first="Svetlana" last="Donina">Svetlana Donina</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Desheva, Julia" sort="Desheva, Julia" uniqKey="Desheva J" first="Julia" last="Desheva">Julia Desheva</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Holman, Robert C" sort="Holman, Robert C" uniqKey="Holman R" first="Robert C" last="Holman">Robert C. Holman</name><affiliation><mods:affiliation>Office of the Director, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop A-39, Atlanta, GA, USA</mods:affiliation></affiliation></author><author><name sortKey="Deguzman, Angel" sort="Deguzman, Angel" uniqKey="Deguzman A" first="Angel" last="Deguzman">Angel Deguzman</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Cox, Nancy J" sort="Cox, Nancy J" uniqKey="Cox N" first="Nancy J" last="Cox">Nancy J. Cox</name><affiliation><mods:affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</mods:affiliation></affiliation></author><author><name sortKey="Katz, Jacqueline M" sort="Katz, Jacqueline M" uniqKey="Katz J" first="Jacqueline M" last="Katz">Jacqueline M. Katz</name><affiliation><mods:affiliation>E-mail: jmk9@cdc.gov</mods:affiliation></affiliation><affiliation><mods:affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:06F7B956F585967015B4D7427F7977B97918802D</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S0264-410X(00)00153-5</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-K0GQW0L3-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000968</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000968</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents</title><author><name sortKey="Rudenko, Larisa G" sort="Rudenko, Larisa G" uniqKey="Rudenko L" first="Larisa G" last="Rudenko">Larisa G. Rudenko</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Arden, Nancy H" sort="Arden, Nancy H" uniqKey="Arden N" first="Nancy H" last="Arden">Nancy H. Arden</name><affiliation><mods:affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</mods:affiliation></affiliation></author><author><name sortKey="Grigorieva, Elena" sort="Grigorieva, Elena" uniqKey="Grigorieva E" first="Elena" last="Grigorieva">Elena Grigorieva</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Naychin, Anatoli" sort="Naychin, Anatoli" uniqKey="Naychin A" first="Anatoli" last="Naychin">Anatoli Naychin</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Rekstin, Andrei" sort="Rekstin, Andrei" uniqKey="Rekstin A" first="Andrei" last="Rekstin">Andrei Rekstin</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Klimov, Alexander I" sort="Klimov, Alexander I" uniqKey="Klimov A" first="Alexander I" last="Klimov">Alexander I. Klimov</name><affiliation><mods:affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</mods:affiliation></affiliation></author><author><name sortKey="Donina, Svetlana" sort="Donina, Svetlana" uniqKey="Donina S" first="Svetlana" last="Donina">Svetlana Donina</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Desheva, Julia" sort="Desheva, Julia" uniqKey="Desheva J" first="Julia" last="Desheva">Julia Desheva</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Holman, Robert C" sort="Holman, Robert C" uniqKey="Holman R" first="Robert C" last="Holman">Robert C. Holman</name><affiliation><mods:affiliation>Office of the Director, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop A-39, Atlanta, GA, USA</mods:affiliation></affiliation></author><author><name sortKey="Deguzman, Angel" sort="Deguzman, Angel" uniqKey="Deguzman A" first="Angel" last="Deguzman">Angel Deguzman</name><affiliation><mods:affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</mods:affiliation></affiliation></author><author><name sortKey="Cox, Nancy J" sort="Cox, Nancy J" uniqKey="Cox N" first="Nancy J" last="Cox">Nancy J. Cox</name><affiliation><mods:affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</mods:affiliation></affiliation></author><author><name sortKey="Katz, Jacqueline M" sort="Katz, Jacqueline M" uniqKey="Katz J" first="Jacqueline M" last="Katz">Jacqueline M. Katz</name><affiliation><mods:affiliation>E-mail: jmk9@cdc.gov</mods:affiliation></affiliation><affiliation><mods:affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">2–3</biblScope><biblScope unit="page" from="308">308</biblScope><biblScope unit="page" to="318">318</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antibody response</term><term>Antibody responses</term><term>Antibody titers</term><term>Attenuated</term><term>Attenuated vaccine</term><term>Chronic diseases</term><term>Clin microbiol</term><term>Combination vaccine groups</term><term>Combination vaccine strategies</term><term>Disease control</term><term>Dos</term><term>Elderly people</term><term>Elderly persons</term><term>Gmt</term><term>Immunogenicity</term><term>Intranasal</term><term>Nasal</term><term>Nursing home</term><term>Nursing home residents</term><term>Nursing homes</term><term>Other vaccine groups</term><term>Placebo</term><term>Placebo group</term><term>Post rise</term><term>Posta riseb</term><term>Postvaccination</term><term>Postvaccination gmts</term><term>Postvaccination serum</term><term>Postvaccination titers</term><term>Prevaccination</term><term>Prevaccination titers</term><term>Reassortant</term><term>Responder</term><term>Rudenko</term><term>Serum antibody response</term><term>Study participants</term><term>Titer</term><term>Treatment groups</term><term>Trivalent</term><term>Trivalent vaccine</term><term>Trivalent vaccines</term><term>Vaccination</term><term>Vaccine</term><term>Vaccine antigens</term><term>Vaccine group</term><term>Vaccine groups</term><term>Vaccine immunogenicity</term><term>Virus vaccine</term><term>Virus vaccines</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The immunogenicity and efficacy of Russian live attenuated and US inactivated trivalent influenza vaccines administered alone or in three different combinations were evaluated in a randomized, placebo-controlled, double-blinded study of 614 elderly or chronically ill nursing home residents in St. Petersburg, Russia during the 1996–97 influenza season. Postvaccination serum antibody responses were more frequent among individuals administered the combination vaccines than among those vaccinated with live or inactivated vaccine alone. Only individuals who received live vaccine, alone or in combination with inactivated vaccine, achieved significant postvaccination increases in virus-specific nasal IgA. Efficacy in preventing laboratory-confirmed influenza in vaccinated versus nonvaccinated individuals was 67% (95%CI, 36–81%) for recipients of a combination of the vaccines compared with 51% (95%CI, −17–79%) for recipients of live vaccine alone and 50% (95%CI, −26–80%) for recipients of inactivated vaccine alone. These results suggest that administration of a combination of influenza vaccines may provide a strategy for improved influenza vaccination of elderly people.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>vaccine</json:string><json:string>postvaccination</json:string><json:string>attenuated</json:string><json:string>trivalent</json:string><json:string>prevaccination</json:string><json:string>placebo</json:string><json:string>rudenko</json:string><json:string>immunogenicity</json:string><json:string>gmt</json:string><json:string>vaccine groups</json:string><json:string>nursing home residents</json:string><json:string>prevaccination titers</json:string><json:string>attenuated vaccine</json:string><json:string>elderly persons</json:string><json:string>placebo group</json:string><json:string>vaccine group</json:string><json:string>vaccination</json:string><json:string>responder</json:string><json:string>reassortant</json:string><json:string>antibody responses</json:string><json:string>postvaccination serum</json:string><json:string>vaccine antigens</json:string><json:string>nursing homes</json:string><json:string>virus vaccines</json:string><json:string>treatment groups</json:string><json:string>titer</json:string><json:string>disease control</json:string><json:string>antibody titers</json:string><json:string>trivalent vaccines</json:string><json:string>postvaccination gmts</json:string><json:string>study participants</json:string><json:string>nasal</json:string><json:string>dos</json:string><json:string>other vaccine groups</json:string><json:string>chronic diseases</json:string><json:string>virus vaccine</json:string><json:string>antibody response</json:string><json:string>nursing home</json:string><json:string>trivalent vaccine</json:string><json:string>intranasal</json:string><json:string>combination vaccine groups</json:string><json:string>posta riseb</json:string><json:string>elderly people</json:string><json:string>serum antibody response</json:string><json:string>vaccine immunogenicity</json:string><json:string>post rise</json:string><json:string>postvaccination titers</json:string><json:string>clin microbiol</json:string><json:string>combination vaccine strategies</json:string></teeft></keywords><author><json:item><name>Larisa G Rudenko</name><affiliations><json:string>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</json:string></affiliations></json:item><json:item><name>Nancy H Arden</name><affiliations><json:string>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</json:string></affiliations></json:item><json:item><name>Elena Grigorieva</name><affiliations><json:string>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</json:string></affiliations></json:item><json:item><name>Anatoli Naychin</name><affiliations><json:string>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</json:string></affiliations></json:item><json:item><name>Andrei Rekstin</name><affiliations><json:string>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</json:string></affiliations></json:item><json:item><name>Alexander I Klimov</name><affiliations><json:string>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</json:string></affiliations></json:item><json:item><name>Svetlana Donina</name><affiliations><json:string>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</json:string></affiliations></json:item><json:item><name>Julia Desheva</name><affiliations><json:string>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</json:string></affiliations></json:item><json:item><name>Robert C Holman</name><affiliations><json:string>Office of the Director, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop A-39, Atlanta, GA, USA</json:string></affiliations></json:item><json:item><name>Angel DeGuzman</name><affiliations><json:string>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</json:string></affiliations></json:item><json:item><name>Nancy J Cox</name><affiliations><json:string>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</json:string></affiliations></json:item><json:item><name>Jacqueline M Katz</name><affiliations><json:string>E-mail: jmk9@cdc.gov</json:string><json:string>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Influenza vaccines</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Clinical studies</value></json:item></subject><arkIstex>ark:/67375/6H6-K0GQW0L3-C</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: The immunogenicity and efficacy of Russian live attenuated and US inactivated trivalent influenza vaccines administered alone or in three different combinations were evaluated in a randomized, placebo-controlled, double-blinded study of 614 elderly or chronically ill nursing home residents in St. Petersburg, Russia during the 1996–97 influenza season. Postvaccination serum antibody responses were more frequent among individuals administered the combination vaccines than among those vaccinated with live or inactivated vaccine alone. Only individuals who received live vaccine, alone or in combination with inactivated vaccine, achieved significant postvaccination increases in virus-specific nasal IgA. Efficacy in preventing laboratory-confirmed influenza in vaccinated versus nonvaccinated individuals was 67% (95%CI, 36–81%) for recipients of a combination of the vaccines compared with 51% (95%CI, −17–79%) for recipients of live vaccine alone and 50% (95%CI, −26–80%) for recipients of inactivated vaccine alone. These results suggest that administration of a combination of influenza vaccines may provide a strategy for improved influenza vaccination of elderly people.</abstract><qualityIndicators><score>8.884</score><pdfWordCount>6524</pdfWordCount><pdfCharCount>41353</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>11</pdfPageCount><pdfPageSize>595 x 842 pts (A4)</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>157</abstractWordCount><abstractCharCount>1190</abstractCharCount><keywordCount>2</keywordCount></qualityIndicators><title>Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents</title><pmid><json:string>10930686</json:string></pmid><pii><json:string>S0264-410X(00)00153-5</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Vaccine</title><language><json:string>unknown</json:string></language><publicationDate>2001</publicationDate><issn><json:string>0264-410X</json:string></issn><pii><json:string>S0264-410X(00)X0113-2</json:string></pii><volume>19</volume><issue>2–3</issue><pages><first>308</first><last>318</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2000</json:string><json:string>1972</json:string><json:string>From 1993 through 1997</json:string><json:string>1996</json:string></date><geogName></geogName><orgName><json:string>Russia In</json:string><json:string>Jackson Immunoresearch Labs Inc.</json:string><json:string>Clinical Research Statistical Support, Abbott Laboratories</json:string><json:string>Elsevier Science Ltd</json:string><json:string>Division of Viral</json:string><json:string>World Health Organization</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>IgA</json:string><json:string>Wyeth Ayerst</json:string><json:string>William Thompson</json:string><json:string>Ira Longini</json:string><json:string>Thomas Rowe</json:string><json:string>Ann Arbor</json:string><json:string>John O'Connor</json:string><json:string>Yuri Ghendon</json:string></persName><placeName><json:string>GA</json:string><json:string>West Grove</json:string><json:string>Moscow</json:string><json:string>Atlanta</json:string><json:string>USA</json:string><json:string>Harbin</json:string><json:string>Leningrad</json:string><json:string>Puri</json:string><json:string>St. Petersburg</json:string><json:string>Russia</json:string><json:string>St Petersburg</json:string><json:string>PA</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[4]</json:string><json:string>[34,37]</json:string><json:string>[10,11]</json:string><json:string>[34]</json:string><json:string>Treanor et al. [32]</json:string><json:string>[44]</json:string><json:string>[39]</json:string><json:string>Control and Prevention, 1600</json:string><json:string>[32]</json:string><json:string>[49]</json:string><json:string>20 January to 2 March, 1997</json:string><json:string>[42]</json:string><json:string>[31,34]</json:string><json:string>[41]</json:string><json:string>[36]</json:string><json:string>L.G. Rudenko et al.</json:string><json:string>[40]</json:string><json:string>[35]</json:string><json:string>[16,17]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-K0GQW0L3-C</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, research & experimental</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Public Health, Environmental and Occupational Health</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Veterinary</json:string><json:string>3 - General Veterinary</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - General Immunology and Microbiology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Molecular Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - pathologie infectieuse</json:string></inist></categories><publicationDate>2001</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1016/S0264-410X(00)00153-5</json:string></doi><id>06F7B956F585967015B4D7427F7977B97918802D</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-K0GQW0L3-C/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-K0GQW0L3-C/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-K0GQW0L3-C/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>2000</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Fig. 1: Percentages of individuals in each vaccine group achieving postvaccination serum HI titers of ⩾40, ⩾80, or ⩾160. Multiple comparisons between treatment groups were performed using a Bonferroni step-down adjustment. Significant p-values between the different groups receiving one or both vaccines (groups I–V) were obtained for the following comparisons: percentages of individuals achieving antibody titers of ⩾40 against A/H3N2, groups I, II, and V, were higher than those of group IV (p⩽0.01, p⩽0.03 and p⩽0.01, respectively); percentages of individuals achieving antibody titers of ⩾40 against A/H1N1, groups I, II, III, were higher than those of group V (p⩽0.05); ⩾80 against A/H1N1, groups I, II, III, and IV were higher than group V (p<0.001 for groups I, II or III, p<0.01 for group V); ⩾160 on A/H1N1, groups I, II, III and IV, were higher than group V (p=0.03, p<0.01, p<0.01, p=0.05, respectively).</note><note type="content">Table 1: Characteristics of 1996–97 study participants by vaccine group</note><note type="content">Table 2: Serum HI antibody responses of nursing home residents to vaccination with intranasal live attenuated trivalent influenza vaccine, inactivated trivalent influenza vaccine, or combinations of both vaccines</note><note type="content">Table 3: Frequency of serum HI antibody rises in individuals with prevaccination titers of <20 or ⩾20</note><note type="content">Table 4: Nasal IgA antibody responses of nursing home residents to vaccination with intranasal live attenuated trivalent influenza vaccine, inactivated trivalent influenza vaccine or combinations of both vaccines</note><note type="content">Table 5: Vaccine efficacy estimates for live attenuated and inactivated vaccines administered alone or in combination to nursing home residents in St. Petersburg, 1996–97 influenza season</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents</title><author xml:id="author-0000"><persName><forename type="first">Larisa G</forename><surname>Rudenko</surname></persName><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Nancy H</forename><surname>Arden</surname></persName><affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Elena</forename><surname>Grigorieva</surname></persName><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Anatoli</forename><surname>Naychin</surname></persName><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Andrei</forename><surname>Rekstin</surname></persName><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Alexander I</forename><surname>Klimov</surname></persName><affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Svetlana</forename><surname>Donina</surname></persName><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation></author><author xml:id="author-0007"><persName><forename type="first">Julia</forename><surname>Desheva</surname></persName><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation></author><author xml:id="author-0008"><persName><forename type="first">Robert C</forename><surname>Holman</surname></persName><affiliation>Office of the Director, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop A-39, Atlanta, GA, USA</affiliation></author><author xml:id="author-0009"><persName><forename type="first">Angel</forename><surname>DeGuzman</surname></persName><note type="biography">Present address: Abbott Diagnostic Division, Clinical Research Statistical Support, Abbott Laboratories, D-7B2 Building AP5N, 100 Abbott Park Road, Abbott Park North, IL 60064-6070, USA</note><affiliation>Present address: Abbott Diagnostic Division, Clinical Research Statistical Support, Abbott Laboratories, D-7B2 Building AP5N, 100 Abbott Park Road, Abbott Park North, IL 60064-6070, USA</affiliation><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation></author><author xml:id="author-0010"><persName><forename type="first">Nancy J</forename><surname>Cox</surname></persName><affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</affiliation></author><author xml:id="author-0011"><persName><forename type="first">Jacqueline M</forename><surname>Katz</surname></persName><email>jmk9@cdc.gov</email><note type="correspondence"><p>Corresponding author. Tel. +1-404-639-3591; fax: +1-404-639-2334</p></note><affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</affiliation></author><idno type="istex">06F7B956F585967015B4D7427F7977B97918802D</idno><idno type="ark">ark:/67375/6H6-K0GQW0L3-C</idno><idno type="DOI">10.1016/S0264-410X(00)00153-5</idno><idno type="PII">S0264-410X(00)00153-5</idno></analytic><monogr><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="pISSN">0264-410X</idno><idno type="PII">S0264-410X(00)X0113-2</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001"></date><biblScope unit="volume">19</biblScope><biblScope unit="issue">2–3</biblScope><biblScope unit="page" from="308">308</biblScope><biblScope unit="page" to="318">318</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: The immunogenicity and efficacy of Russian live attenuated and US inactivated trivalent influenza vaccines administered alone or in three different combinations were evaluated in a randomized, placebo-controlled, double-blinded study of 614 elderly or chronically ill nursing home residents in St. Petersburg, Russia during the 1996–97 influenza season. Postvaccination serum antibody responses were more frequent among individuals administered the combination vaccines than among those vaccinated with live or inactivated vaccine alone. Only individuals who received live vaccine, alone or in combination with inactivated vaccine, achieved significant postvaccination increases in virus-specific nasal IgA. Efficacy in preventing laboratory-confirmed influenza in vaccinated versus nonvaccinated individuals was 67% (95%CI, 36–81%) for recipients of a combination of the vaccines compared with 51% (95%CI, −17–79%) for recipients of live vaccine alone and 50% (95%CI, −26–80%) for recipients of inactivated vaccine alone. These results suggest that administration of a combination of influenza vaccines may provide a strategy for improved influenza vaccination of elderly people.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Influenza vaccines</term></item><item><term>Clinical studies</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2000-04-12">Modified</change><change when="2001">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-K0GQW0L3-C/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: ce:floats; body; tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"><istex:entity SYSTEM="gr1" NDATA="IMAGE" name="gr1"></istex:entity></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>JVAC</jid><aid>2157</aid><ce:pii>S0264-410X(00)00153-5</ce:pii><ce:doi>10.1016/S0264-410X(00)00153-5</ce:doi><ce:copyright type="us-gov" year="2000"></ce:copyright></item-info><head><ce:title>Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents</ce:title><ce:author-group><ce:author><ce:given-name>Larisa G</ce:given-name><ce:surname>Rudenko</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Nancy H</ce:given-name><ce:surname>Arden</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Elena</ce:given-name><ce:surname>Grigorieva</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Anatoli</ce:given-name><ce:surname>Naychin</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Andrei</ce:given-name><ce:surname>Rekstin</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Alexander I</ce:given-name><ce:surname>Klimov</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Svetlana</ce:given-name><ce:surname>Donina</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Julia</ce:given-name><ce:surname>Desheva</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Robert C</ce:given-name><ce:surname>Holman</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>c</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Angel</ce:given-name><ce:surname>DeGuzman</ce:surname><ce:cross-ref refid="FN1"><ce:sup>1</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Nancy J</ce:given-name><ce:surname>Cox</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Jacqueline M</ce:given-name><ce:surname>Katz</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>b</ce:sup></ce:cross-ref><ce:cross-ref refid="CORR1">*</ce:cross-ref><ce:e-address>jmk9@cdc.gov</ce:e-address></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>c</ce:label><ce:textfn>Office of the Director, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop A-39, Atlanta, GA, USA</ce:textfn></ce:affiliation><ce:correspondence id="CORR1"><ce:label>*</ce:label><ce:text>Corresponding author. Tel. +1-404-639-3591; fax: +1-404-639-2334</ce:text></ce:correspondence><ce:footnote id="FN1"><ce:label>1</ce:label><ce:note-para>Present address: Abbott Diagnostic Division, Clinical Research Statistical Support, Abbott Laboratories, D-7B2 Building AP5N, 100 Abbott Park Road, Abbott Park North, IL 60064-6070, USA</ce:note-para></ce:footnote></ce:author-group><ce:date-received day="19" month="1" year="2000"></ce:date-received><ce:date-revised day="12" month="4" year="2000"></ce:date-revised><ce:date-accepted day="12" month="4" year="2000"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>The immunogenicity and efficacy of Russian live attenuated and US inactivated trivalent influenza vaccines administered alone or in three different combinations were evaluated in a randomized, placebo-controlled, double-blinded study of 614 elderly or chronically ill nursing home residents in St. Petersburg, Russia during the 1996–97 influenza season. Postvaccination serum antibody responses were more frequent among individuals administered the combination vaccines than among those vaccinated with live or inactivated vaccine alone. Only individuals who received live vaccine, alone or in combination with inactivated vaccine, achieved significant postvaccination increases in virus-specific nasal IgA. Efficacy in preventing laboratory-confirmed influenza in vaccinated versus nonvaccinated individuals was 67% (95%CI, 36–81%) for recipients of a combination of the vaccines compared with 51% (95%CI, −17–79%) for recipients of live vaccine alone and 50% (95%CI, −26–80%) for recipients of inactivated vaccine alone. These results suggest that administration of a combination of influenza vaccines may provide a strategy for improved influenza vaccination of elderly people.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="keyword"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Influenza vaccines</ce:text></ce:keyword><ce:keyword><ce:text>Clinical studies</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents</title></titleInfo><name type="personal"><namePart type="given">Larisa G</namePart><namePart type="family">Rudenko</namePart><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nancy H</namePart><namePart type="family">Arden</namePart><affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Elena</namePart><namePart type="family">Grigorieva</namePart><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anatoli</namePart><namePart type="family">Naychin</namePart><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrei</namePart><namePart type="family">Rekstin</namePart><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alexander I</namePart><namePart type="family">Klimov</namePart><affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Svetlana</namePart><namePart type="family">Donina</namePart><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Julia</namePart><namePart type="family">Desheva</namePart><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert C</namePart><namePart type="family">Holman</namePart><affiliation>Office of the Director, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop A-39, Atlanta, GA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Angel</namePart><namePart type="family">DeGuzman</namePart><affiliation>Department of Virology, Institute for Experimental Medicine, 12 Pavlov Street, St. Petersburg, Russia</affiliation><description>Present address: Abbott Diagnostic Division, Clinical Research Statistical Support, Abbott Laboratories, D-7B2 Building AP5N, 100 Abbott Park Road, Abbott Park North, IL 60064-6070, USA</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nancy J</namePart><namePart type="family">Cox</namePart><affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jacqueline M</namePart><namePart type="family">Katz</namePart><affiliation>E-mail: jmk9@cdc.gov</affiliation><affiliation>Influenza Branch, Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop G-16, Atlanta, GA, USA</affiliation><description>Corresponding author. Tel. +1-404-639-3591; fax: +1-404-639-2334</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2001</dateIssued><dateModified encoding="w3cdtf">2000-04-12</dateModified><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: The immunogenicity and efficacy of Russian live attenuated and US inactivated trivalent influenza vaccines administered alone or in three different combinations were evaluated in a randomized, placebo-controlled, double-blinded study of 614 elderly or chronically ill nursing home residents in St. Petersburg, Russia during the 1996–97 influenza season. Postvaccination serum antibody responses were more frequent among individuals administered the combination vaccines than among those vaccinated with live or inactivated vaccine alone. Only individuals who received live vaccine, alone or in combination with inactivated vaccine, achieved significant postvaccination increases in virus-specific nasal IgA. Efficacy in preventing laboratory-confirmed influenza in vaccinated versus nonvaccinated individuals was 67% (95%CI, 36–81%) for recipients of a combination of the vaccines compared with 51% (95%CI, −17–79%) for recipients of live vaccine alone and 50% (95%CI, −26–80%) for recipients of inactivated vaccine alone. These results suggest that administration of a combination of influenza vaccines may provide a strategy for improved influenza vaccination of elderly people.</abstract><note type="content">Fig. 1: Percentages of individuals in each vaccine group achieving postvaccination serum HI titers of ⩾40, ⩾80, or ⩾160. Multiple comparisons between treatment groups were performed using a Bonferroni step-down adjustment. Significant p-values between the different groups receiving one or both vaccines (groups I–V) were obtained for the following comparisons: percentages of individuals achieving antibody titers of ⩾40 against A/H3N2, groups I, II, and V, were higher than those of group IV (p⩽0.01, p⩽0.03 and p⩽0.01, respectively); percentages of individuals achieving antibody titers of ⩾40 against A/H1N1, groups I, II, III, were higher than those of group V (p⩽0.05); ⩾80 against A/H1N1, groups I, II, III, and IV were higher than group V (p<0.001 for groups I, II or III, p<0.01 for group V); ⩾160 on A/H1N1, groups I, II, III and IV, were higher than group V (p=0.03, p<0.01, p<0.01, p=0.05, respectively).</note><note type="content">Table 1: Characteristics of 1996–97 study participants by vaccine group</note><note type="content">Table 2: Serum HI antibody responses of nursing home residents to vaccination with intranasal live attenuated trivalent influenza vaccine, inactivated trivalent influenza vaccine, or combinations of both vaccines</note><note type="content">Table 3: Frequency of serum HI antibody rises in individuals with prevaccination titers of <20 or ⩾20</note><note type="content">Table 4: Nasal IgA antibody responses of nursing home residents to vaccination with intranasal live attenuated trivalent influenza vaccine, inactivated trivalent influenza vaccine or combinations of both vaccines</note><note type="content">Table 5: Vaccine efficacy estimates for live attenuated and inactivated vaccines administered alone or in combination to nursing home residents in St. Petersburg, 1996–97 influenza season</note><subject><genre>Keywords</genre><topic>Influenza vaccines</topic><topic>Clinical studies</topic></subject><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><titleInfo type="abbreviated"><title>JVAC</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2001</dateIssued></originInfo><identifier type="ISSN">0264-410X</identifier><identifier type="PII">S0264-410X(00)X0113-2</identifier><part><date>2001</date><detail type="volume"><number>19</number><caption>vol.</caption></detail><detail type="issue"><number>2–3</number><caption>no.</caption></detail><extent unit="issue-pages"><start>155</start><end>384</end></extent><extent unit="pages"><start>308</start><end>318</end></extent></part></relatedItem><identifier type="istex">06F7B956F585967015B4D7427F7977B97918802D</identifier><identifier type="ark">ark:/67375/6H6-K0GQW0L3-C</identifier><identifier type="DOI">10.1016/S0264-410X(00)00153-5</identifier><identifier type="PII">S0264-410X(00)00153-5</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-K0GQW0L3-C/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000968 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000968 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:06F7B956F585967015B4D7427F7977B97918802D
|texte= Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents
}}
| This area was generated with Dilib version V0.6.33. |  |